Andrew Rhinehart, MD, chief medical officer at Glytec, discusses the transition from intermediate outcomes in diabetes research of glycemic results to harder outcomes that will benefit the patient financially and through their care.
Andrew Rhinehart, MD, chief medical officer at Glytec, discusses the transition from intermediate outcomes in diabetes research of glycemic results to harder outcomes that will benefit the patient financially and through their care.
Transcript (slightly modified)
Can you describe the transition in diabetes research from focusing on glycemic results to costs for health systems?
Over the last year or so we’ve made a concerted effort to switch our evidence strategy from that of solely glycemic control to one of the hard outcomes. We call the glucose control more of an intermediary outcome and we know that we can reduce hypoglycemia in hospitals. We know that we can reduce hypoglycemia and keep people in that glucose target range more frequently.
Now what we want to do, and what we have done, is proven that improving that intermediate outcome actually improves the harder outcomes. The hard outcomes to me, especially as a clinician, are length of stay so my patients can go home sooner from the hospital, readmissions so my patients don’t have to come back in the hospital, obviously both of those are advantageous, but we can also reduce infection rates etc. So, that’s what we have targeting here over the last little bit, making sure that glucose control translates into those harder outcomes and the financial outcomes that they reward as well.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
April 2nd 2025Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More